thiophenes has been researched along with Thromboembolism, Venous in 276 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (15.58) | 29.6817 |
| 2010's | 233 (84.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crowther, MA; Cuker, A | 1 |
| Álvarez-Gutierrez, A; Cooper, C; Delmestri, A; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Llorente-Garcia, A; Martín-Merino, E; Petersen, I; Prieto-Alhambra, D; Van Staa, TP | 1 |
| Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H | 1 |
| Ageno, W; Ferrari, A; Filippi, A; Imberti, D; Palareti, G; Pengo, V; Rubboli, A; Toni, D | 1 |
| Beyer-Westendorf, J; Gehrisch, S; Mahlmann, A | 1 |
| Ageno, W; Bozzato, S; Donadini, MP; Riva, N | 1 |
| Akwaa, F; Spyropoulos, AC | 2 |
| Guijarro Merino, R; Villalobos Sánchez, A | 1 |
| Marchena Yglesias, PJ | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P | 1 |
| Forster, MC; Goodson, MW; Rath, NK; White, SP | 1 |
| Ageno, W; Buller, H; Glazer, S; Gunn, S; Peerlinck, K; Prins, M; Sonesson, E; Tangelder, M; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Cohen, AT; Spiro, TE; Spyropoulos, AC | 1 |
| Alameddine, R; Husari, A | 1 |
| Derksen, RJ; Mulder, JW; Mulder, WM | 1 |
| Sohne, M; Vink, R | 1 |
| Dentali, F; Riva, N | 1 |
| Einecke, D | 1 |
| Cutler, NR; Goldenberg, NA; Halperin, JL; Hiatt, WR; Kessler, CM; Kittelson, JM; Schulman, S; Spyropoulos, AC; Steg, G; Turpie, AG | 1 |
| Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Páramo, JA | 1 |
| Bertoletti, L; Buchmuller, A; Decousus, H; Lega, JC; Mismetti, P; Moulin, N | 1 |
| Wanat, MA | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Lu, WX; Qin, L | 1 |
| Brown, TS; Huo, MH | 1 |
| Atar, D; Ghanima, W; Sandset, PM | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Ragni, MV; Seaman, CD; Smith, KJ | 1 |
| Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M | 1 |
| Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM | 1 |
| Dütsch, M; Klauser, W | 1 |
| Kreutz, R | 2 |
| Laffan, M; Shapiro, S | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Adcock, DM; Deal, AM; Francart, SJ; Friedman, KD; Gosselin, R; Hawes, EM; Jeanneret, C; Moll, S | 1 |
| Jiang, B; Li, H; Long, A; Mao, Z; Tang, P; Xie, Z; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Burness, CB; Perry, CM | 1 |
| Schulman, S | 4 |
| Büller, HR; Burton, P; Cohen, AT; Desanctis, YH; Haskell, L; Homering, M; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Du, EX; Li, N; Liu, Y; Tan, R; Wu, C; Wu, EQ; Xie, J | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Bareket, Y; Bennett, W; Thomas, Z | 1 |
| Bookhart, BK; Coleman, CI; Limone, BL; Mody, SH; Nutescu, EA | 1 |
| Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z | 1 |
| Thachil, J | 1 |
| Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S | 1 |
| Brieger, D | 1 |
| Amann, U; Enders, D; Garbe, E; Jobski, K; Schink, T; Suzart, K; Wallander, MA | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Lévy, S | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 3 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Lip, GY; Shantsila, E | 1 |
| Büller, HR; Cohen, AT; De Sanctis, Y; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, SW; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Rodgers, GM; Win, K | 1 |
| Baumann, M; Ceschi, A; Hasler, K; Hofer, KE; Korte, W; Kupferschmidt, H; Lehmann, T; Rohde, G | 1 |
| Ay, C; Hayde, M; Königsbrügge, O; Langer, M; Pabinger, I | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Fleet, JL; Garg, AX; Lazo-Langner, A; McArthur, E | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Dupree, LH; Reddy, P | 1 |
| Dobesh, PP; Trujillo, T | 1 |
| Conway, SE; Mitchell, AP | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Bolland, MJ; Grey, A | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Cui, J; Li, Z; Liu, C; Wu, B | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 3 |
| Auckenthaler, T; Innerhofer, P; Oswald, E; Streif, W; Tauber, H; Ulmer, H; Velik-Salchner, C | 1 |
| Peerlinck, K; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Arachchillage, DR; Cohen, H; Efthymiou, M; Lawrie, AS; Machin, SJ; Mackie, IJ | 1 |
| Giannoukas, AD; Spanos, K | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Bozhkova, SA; Drozdova, PV; Novokshonova, AA | 1 |
| Trusler, M | 1 |
| Ansell, JE; Cabral, KP | 1 |
| Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC | 1 |
| Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL | 1 |
| Handa, A; Hurst, KV; Lee, R; Milosevic, I | 1 |
| Kreher, S; Riess, H; Sinn, M | 1 |
| Bächli, E; Walti, C | 1 |
| Bartle, B; Bond, AM; McFee Winans, AR; Rudd, KM | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Bansal, VB; Donovan, A; Gollish, JD; Gomez, D; Murnaghan, JJ; Razmjou, H | 1 |
| Beyer-Westendorf, J | 1 |
| Bandel, TJ; Beckmann, H; Borris, LC; Eriksson, BI; Friedman, RJ; Geerts, W; Haas, S; Huisman, MV; Kakkar, AK; Misselwitz, F; Muehlhofer, E | 1 |
| Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG | 1 |
| Becker, RC; Lohrmann, J | 1 |
| Eikelboom, JW; Weitz, JI | 2 |
| Brenner, B; Dahl, OE; Eriksson, BI; Haas, S; Kakkar, AK; Misselwitz, F; Mouret, P; Muntz, J; Pap, AF; Soglian, AG | 1 |
| Gulseth, MP; Michaud, J; Nutescu, EA | 1 |
| Douglas, I; Grosso, A; Hingorani, A; MacAllister, R; Smeeth, L | 1 |
| Borris, LC; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F; Mueck, W; Muelhofer, E | 1 |
| Turpie, AG | 1 |
| Spyropoulos, AC | 1 |
| Beyer, J; Hochauf, S | 1 |
| Paramanathan, V | 1 |
| Schuman, EP | 1 |
| Franchini, M; Lippi, G; Targher, G | 1 |
| Lotke, PA | 1 |
| Hamulyak, K; ten Cate, H | 1 |
| Borris, LC | 2 |
| Garcia Nuño, L; Granero Xiberta, J; Soler Minoves, JM | 1 |
| Ferrandis, R; Llau, JV; López Forte, C; Sapena, ML | 1 |
| Haas, S | 1 |
| Farley, TM; Lewis, D; Macaulay, TE | 1 |
| Tripodi, A; van den Besselaar, A | 1 |
| Lassen, MR; Laux, V | 1 |
| Harenberg, J; Nitschmann, S | 1 |
| Bandel, TJ; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG | 1 |
| Becker, RC | 1 |
| Kamphuisen, PW; Leebeek, FW | 1 |
| Arya, R; Roberts, LN | 1 |
| Boyle, AJ; Yong, CM | 1 |
| Ageno, W | 1 |
| Crowther, MA; Lepic, K | 1 |
| Perzborn, E | 1 |
| Duggan, ST; Plosker, GL; Scott, LJ | 1 |
| Levine, MN | 1 |
| Barry, M; McCullagh, L; Tilson, L; Walsh, C | 1 |
| Breart, G; Cooper, C; Deltour, N; Meyer, O; Reginster, JY; Speirs, C | 1 |
| Holmes, M; Kaltenthaler, E; Rees, A; Scope, A; Stevenson, M | 1 |
| Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 1 |
| Wittkowsky, AK | 1 |
| Fassiadis, N | 1 |
| Conard, J; Horellou, MH; Samama, MM | 1 |
| Verma, AK | 1 |
| Dick, W; Saxer, F | 1 |
| Clayton, RA; Gaston, P; Howie, CR | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Bauer, KA | 1 |
| Exter, BP; Jarvis, CI; Melillo, SN; Scanlon, JV; Steinberg, M | 1 |
| Cohen, AT; Nandini, B; Ota, S; Wills, JO | 1 |
| Layton, D; Osborne, V; Perrio, M; Shakir, SA; Wilton, L | 1 |
| Harber, CR; Nathanson, MH | 1 |
| Drabu, KJ; Foote, J; Phillips, S; Rogers, BA | 1 |
| Shakib, S; Tadros, R | 1 |
| Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS | 1 |
| Cao, YB; Jiang, YY; Shen, H; Zhang, JD | 1 |
| Clemens, A; Monz, BU; Plumb, JM | 1 |
| Crowther, M; Lepic, K | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Chitolie, A; Green, L; Haddad, FS; Hossain, F; Lawrie, AS; Machin, SJ; Mackie, IJ; Patel, S | 1 |
| Barrett, YC; Frost, C; Shenker, A; Wang, Z | 1 |
| Giannoudis, PV; Harwood, PJ; Karadimas, EJ; Nikolaou, VS; Tan, HB | 1 |
| Morris, TA | 1 |
| Butler, J; Gan, E; Kaplan, Z; Malan, E; Merriman, E; Tran, H | 1 |
| Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Bandel, TJ; Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG; Westermeier, T | 1 |
| Hylek, EM | 1 |
| Weitz, JI | 1 |
| Foote, J; Phillips, SN; Rogers, BA | 1 |
| Kwok, CS; Loke, YK | 1 |
| Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, A; Tapson, V | 1 |
| Ageno, W; Romualdi, E | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Banghua, L; Jin, C; Turun, S; Ying, N; Yuan, Y; Zhenhui, L | 1 |
| Samama, CM | 1 |
| Ageno, W; Streif, W | 1 |
| Giannoudis, PV; Goff, T; Kontakis, G | 1 |
| Braunwald, E; Steffel, J | 1 |
| Berkowitz, SD; Misselwitz, F; Perzborn, E | 1 |
| Cerbone, AM; Coppola, A; Franchini, M; Ruosi, C; Tufano, A | 1 |
| Fisher, WD | 1 |
| Kwong, LM | 4 |
| Nutescu, E | 1 |
| Merli, G | 2 |
| Friedman, RJ | 2 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Fareed, J; Hull, R; Welzel, D | 1 |
| Keltai, K; Keltai, M | 1 |
| Hesse, C; Lindhoff-Last, E; Mani, H; Stratmann, G | 1 |
| Friedman, RJ; Lees, M; Sengupta, N | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Ageno, W; Donadini, MP; Romualdi, E | 1 |
| Asmis, LM | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Jaeger, M; Jeanneret, B; Schaeren, S | 1 |
| Beer, JH | 1 |
| Björholt, I; Diamantopoulos, A; Forster, F; Fraschke, A; Lees, M; Ryttberg, L | 1 |
| Blombery, PA | 1 |
| Diamantopoulos, A; Duran, A; Forster, F; Kwong, L; Lees, M; Sengupta, N | 2 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N | 1 |
| Duggan, ST | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Cohen, AT; Dobromirski, M | 1 |
| Lee, S; White, CM | 1 |
| Mahan, C; Spyropoulos, AC | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Lip, GY; Shantsila, A | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Ansell, J | 1 |
| Palareti, G; Tripodi, A | 1 |
| Ananthapavan, J; Diamantopoulos, A; Folkerts, K; Forster, F; Lees, M; McDonald, H; Wells, P | 1 |
| Cohen, AT | 1 |
| Belavic, JM | 1 |
| Warwick, D | 1 |
| Kline, JA; Yealy, DM | 1 |
| Augoustides, JG | 1 |
| Barry, M; McCullagh, L; Walsh, C | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Haas, S; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, L; Schmidt, AC; Turpie, AG | 1 |
| Müller, D; Stock, S; Stollenwerk, B; Zindel, S | 1 |
| Pollack, CV | 1 |
| Berkowitz, RD; Damaraju, CV; Jennings, LK; Mills, RM; Wildgoose, P | 1 |
| Beyer-Westendorf, J; Donath, L; Hartmann, A; Kuhlisch, E; Lützner, J; Radke, OC; Weiss, N; Werth, S | 1 |
| Kwong, LM; Tong, LM | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG | 1 |
| Blanco-Molina, A | 1 |
| Elias, A; Gaillard, C; Gouin, I; Nguyen, P; Ouvry, P; Pernod, G; Sié, P | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Lazo-Langner, A; Sun, D | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Albuquerque, LG; Dini, GM; Ferreira, LM; Ferreira, MCC | 1 |
| Hardy, G | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Guo, W; Tang, BQ; Tang, S; Tang, XD; Yan, TQ; Yang, RL | 1 |
| Gulseth, M; Hellwig, T | 1 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Ganetsky, V; Spinler, SA; Thomas, TF | 1 |
| Debue, JM; Guinet, C; Le Flem, L; Ninin, E; Samama, MM | 1 |
| Berkowitz, SD; Homering, M; Llau, JV; Loewe, A; Mueck, W; Rosencher, N | 1 |
| Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, V | 1 |
| Graff, J; Harder, S | 1 |
| Garcia, DA; Rojas-Hernandez, CM | 1 |
| Ma, Q | 1 |
| Gross, PL; Weitz, JI | 1 |
| Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Mueck, W; Turpie, AG | 1 |
| Harenberg, J; Wehling, M | 1 |
126 review(s) available for thiophenes and Thromboembolism, Venous
| Article | Year |
|---|---|
Clinical management of rivaroxaban-treated patients.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Consensus; Drug Interactions; Drug Substitution; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Medication Adherence; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New evidence in the secondary prevention of thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation Products; Humans; Morpholines; Prognosis; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.
Topics: Administration, Oral; Anticoagulants; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Advances in venous thromboembolism].
Topics: Anticoagulants; Hemorrhage; Heparin; Humans; Magnetic Resonance Angiography; Morpholines; Pulmonary Artery; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Tomography, X-Ray Computed; Venous Thromboembolism | 2013 |
New anticoagulants for thromboprophylaxis after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation Tests; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Hematoma, Epidural, Spinal; Humans; Morpholines; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban.
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hip Joint; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Rivaroxaban for treatment of venous thromboembolism in older adults.
Topics: Aged; Aged, 80 and over; Aging; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Pulmonary Embolism; Recurrence; Renal Insufficiency; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record.
Topics: Bone Density Conservation Agents; Drug and Narcotic Control; Humans; Myocardial Infarction; Osteoporosis; Osteoporotic Fractures; Periodicals as Topic; Pulmonary Embolism; Research Report; Risk Assessment; Thiophenes; Venous Thromboembolism | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
The role of factor Xa inhibitors in venous thromboembolism treatment.
Topics: Animals; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
Rivaroxaban: an oral direct inhibitor of factor Xa.
Topics: Aging; Antithrombin III; Clinical Trials as Topic; Drug Interactions; Fibrinolytic Agents; Hepatic Insufficiency; Humans; Morpholines; Obesity; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
The top 4 advances in antithrombotic care in the last year.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban: future in anticoagulation practice?
Topics: Anticoagulants; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.
Topics: Administration, Oral; Animals; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Patient Satisfaction; Quality of Life; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
[Anaesthesia and thromboembolic disease].
Topics: Acenocoumarol; Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; Clinical Protocols; Dabigatran; Early Ambulation; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Risk Factors; Rivaroxaban; Safety; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Topics: Anticoagulants; Antithrombin III; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2009 |
Laboratory monitoring of anticoagulation: where do we stand?
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Incidence; International Normalized Ratio; Monitoring, Physiologic; Morpholines; Polysaccharides; Prothrombin Time; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2009 |
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
New anticoagulants for prevention and treatment of venous thromboembolism.
Topics: Animals; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Humans; Morpholines; Oligosaccharides; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
A logical approach to surgical thromboprophylaxis.
Topics: Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Premedication; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Rivaroxaban in orthopedic surgery--a change of paradigm?
Topics: Anticoagulants; Humans; Morpholines; Orthopedic Procedures; Premedication; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New antithrombotic drugs: potential for use in oncology.
Topics: Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Male; Morpholines; Neoplasms; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
Topics: Adult; Anticoagulants; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New oral anticoagulants: a practical guide for clinicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Evidence-Based Medicine; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
New oral anticoagulants in development: potential for improved safety profiles.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Evaluation; Factor Xa; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2010 |
Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.
Topics: Animals; Clinical Trials, Phase III as Topic; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Morpholines; Multicenter Studies as Topic; Odds Ratio; Primary Prevention; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
New anticoagulants for the prevention of thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism | 2011 |
A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Middle Aged; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Young Adult | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Humans; Lower Extremity; Morpholines; Orthopedics; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
The discovery and development of rivaroxaban.
Topics: Adult; Animals; Clinical Trials as Topic; Drug Design; Drug Discovery; Fibrinolytic Agents; Humans; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Morpholines; Rivaroxaban; Thiophenes; Validation Studies as Topic; Venous Thromboembolism | 2011 |
Preventing postsurgical venous thromboembolism: pharmacological approaches.
Topics: Aged; Anticoagulants; Antithrombins; Arthroscopy; Bariatric Surgery; Benzimidazoles; Blood Coagulation Disorders, Inherited; Dabigatran; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Kidney; Knee; Laparoscopy; Morpholines; Neoplasms; Orthopedic Procedures; Polysaccharides; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost Savings; Health Care Costs; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Topics: Aged; Anticoagulants; Blood Coagulation; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Topics: Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.
Topics: Acute Coronary Syndrome; Anesthesia, Conduction; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Drug interactions with rivaroxaban following total joint replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Advances in the management of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Diagnostic Imaging; Disease Management; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Radiography; Risk; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral therapies for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban: an oral factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
New anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Morpholines; Oligosaccharides; Postphlebitic Syndrome; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism | 2008 |
31 trial(s) available for thiophenes and Thromboembolism, Venous
| Article | Year |
|---|---|
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Patient Safety; Postoperative Complications; Risk; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2013 |
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Techniques; Male; Middle Aged; Morpholines; Platelet Aggregation; Rivaroxaban; Swine; Thiophenes; Thrombosis; Venous Thromboembolism; Young Adult | 2013 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism | 2013 |
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Data Interpretation, Statistical; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Propensity Score; Risk; Rivaroxaban; Standard of Care; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Cross-Sectional Studies; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Point-of-Care Systems; Prothrombin Time; Reference Values; Rivaroxaban; Thiophenes; Venous Thromboembolism; Whole Blood Coagulation Time | 2014 |
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Factor Xa Inhibitors; Female; Fractures, Bone; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Length of Stay; Lower Extremity; Male; Middle Aged; Morpholines; Postoperative Complications; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Morpholines; Multivariate Analysis; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Morpholines; Multivariate Analysis; Predictive Value of Tests; Primary Prevention; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Venous Thromboembolism | 2014 |
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Safety; Thiophenes; Venous Thromboembolism; Vitamin K | 2015 |
[CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study].
Topics: Acute Disease; Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Patient Satisfaction; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2017 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Factor Xa; Female; Humans; Male; Middle Aged; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2009 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; Factor Xa; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Thrombin; Treatment Outcome; Venous Thromboembolism | 2010 |
Rivaroxaban and false positive lupus anticoagulant testing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2010 |
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heart Failure; Humans; Infections; Male; Middle Aged; Morpholines; Pulmonary Embolism; Respiratory Insufficiency; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Morpholines; Risk; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2011 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
How safe is thromboprophylaxis in abdominoplasty?
Topics: Abdominoplasty; Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Hematoma; Humans; Middle Aged; Morpholines; Postoperative Care; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2012 |
[Evaluation of efficacy and safety of rivaroxaban in the prevention of postoperative venous thromboembolism in adult patients with primary bone tumor undergoing knee operation].
Topics: Adult; Anticoagulants; Bone Neoplasms; Female; Humans; Knee; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2012 |
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Hematoma; Humans; Incidence; Male; Middle Aged; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Nonlinear Dynamics; Prothrombin Time; Rivaroxaban; Sex Factors; Thiophenes; Time Factors; Tissue Distribution; Venous Thromboembolism | 2008 |
120 other study(ies) available for thiophenes and Thromboembolism, Venous
| Article | Year |
|---|---|
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism.
Topics: Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes; Veins; Venous Thromboembolism | 2017 |
Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Humans; Male; Middle Aged; Primary Health Care; Risk Assessment; Spain; Teriparatide; Thiophenes; United Kingdom; Venous Thromboembolism | 2018 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemoprevention; Elective Surgical Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Hip; Osteoarthritis, Knee; Outcome and Process Assessment, Health Care; Postoperative Complications; Rivaroxaban; Thiophenes; United Kingdom; Venous Thromboembolism; Wound Healing | 2013 |
Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.
Topics: Adult; Anticoagulants; Bariatric Surgery; Female; Humans; International Normalized Ratio; Morpholines; Obesity, Morbid; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism | 2013 |
The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Case-Control Studies; Female; Follow-Up Studies; Humans; Middle Aged; Morpholines; Postoperative Complications; Primary Prevention; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Rivaroxaban; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Hip; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Questions and answers regarding the use of rivaroxaban in daily practice].
Topics: Administration, Oral; Anticoagulants; General Practice; Humans; Morpholines; Orthopedic Procedures; Rivaroxaban; Switzerland; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Topics: Anticoagulants; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
Topics: Anticoagulants; China; Female; Health Care Costs; Heparin, Low-Molecular-Weight; Hospitalization; Humans; International Normalized Ratio; Logistic Models; Male; Middle Aged; Morpholines; Pulmonary Embolism; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Rivaroxaban use following bariatric surgery.
Topics: Anticoagulants; Bariatric Surgery; Female; Humans; Morpholines; Obesity, Morbid; Thiophenes; Venous Thromboembolism | 2014 |
Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Topics: Anticoagulants; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2014 |
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Databases, Factual; Drug Utilization; Factor Xa Inhibitors; Female; Germany; Hospitals; Humans; Male; Middle Aged; Morpholines; Off-Label Use; Rivaroxaban; Thiophenes; Venous Thromboembolism; Young Adult | 2014 |
Thrombotic complications in heart failure: an underappreciated challenge.
Topics: Enoxaparin; Female; Heart Failure; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Massive human rivaroxaban overdose.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Drug Overdose; Factor Xa; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Suicide, Attempted; Tandem Mass Spectrometry; Thiophenes; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Male; Morpholines; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2014 |
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Hip; Humans; Male; Molecular Weight; Morpholines; Ontario; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability.
Topics: Administration, Oral; Adolescent; Anticoagulants; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Morpholines; Nephrotic Syndrome; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Topics: Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Prospective Studies; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Venous Thromboembolism | 2015 |
Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trial
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
[Aspects of the practical application of direct oral anticoagulants in traumatological and orthopedic hospital].
Topics: Administration, Oral; Anticoagulants; Chemoprevention; Costs and Cost Analysis; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Outcome Assessment, Health Care; Postoperative Complications; Retrospective Studies; Rivaroxaban; Russia; Secondary Prevention; Thiophenes; Traumatology; Venous Thromboembolism | 2014 |
Response.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism | 2015 |
Well-managed warfarin is superior to NOACs.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism | 2015 |
Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult | 2015 |
Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points fo
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Possible Rivaroxaban Failure during the Postpartum Period: An Alternative Viewpoint.
Topics: Anticoagulants; Factor Xa Inhibitors; Female; Humans; Morpholines; Postpartum Period; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2016 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2016 |
New anticoagulants--the path from discovery to clinical practice.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Selective factor Xa inhibition for thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Databases, Factual; Drug Hypersensitivity; Family Practice; Female; Gastrointestinal Diseases; Humans; Memory Disorders; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Product Surveillance, Postmarketing; Risk Assessment; Thiophenes; United Kingdom; Venous Thromboembolism | 2008 |
[Prophylaxis of venous thromboembolism].
Topics: Anticoagulants; Factor Xa; Humans; Inpatients; Laparoscopy; Morpholines; Reoperation; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Body Weight; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Antidotes; Arthroplasty, Replacement; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
[Thromboembolic disease in orthopedic surgery].
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Early Ambulation; Enoxaparin; Fibrinolytic Agents; Hip Fractures; Humans; Intraoperative Care; Morpholines; Orthopedics; Postoperative Care; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism | 2008 |
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
The importance of VTE prevention after orthopaedic surgery.
Topics: Anticoagulants; Cost of Illness; Enoxaparin; Evidence-Based Medicine; Humans; Length of Stay; Morpholines; Orthopedic Procedures; Risk Reduction Behavior; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[The new oral anticoagulant in the Netherlands].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Interactions; Elective Surgical Procedures; Humans; Morpholines; Netherlands; Patient Selection; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Design; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Glycine; Hemostasis; Humans; Morpholines; Piperazines; Pyrazoles; Pyridones; Pyrrolidines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Thiophenes; United Kingdom; Venous Thromboembolism | 2010 |
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denmark; Diphosphonates; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Pulmonary Embolism; Raloxifene Hydrochloride; Thiophenes; Venous Thromboembolism | 2010 |
Rivaroxaban, the first oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2009 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation Tests; Combined Modality Therapy; Drug Approval; Drug Interactions; Early Ambulation; Enoxaparin; Factor Xa Inhibitors; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Orthopedic Procedures; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Stockings, Compression; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Bone Density Conservation Agents; Cohort Studies; Drug Prescriptions; England; Female; Humans; Incidence; Male; Organometallic Compounds; Surveys and Questionnaires; Thiophenes; Venous Thromboembolism | 2010 |
Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
Topics: Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Patient Satisfaction; Postoperative Care; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Factor Xa Inhibitors; Humans; Lower Extremity; Morpholines; Orthopedic Procedures; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Therapeutic potential of oral factor Xa inhibitors.
Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Fibrinolytic Agents; Humans; Morpholines; Postoperative Care; Postoperative Complications; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Health Care Costs; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Clinical Protocols; Drug Interactions; Factor Xa Inhibitors; Female; Fibrinogen; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Postoperative Complications; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban).
Topics: Anticoagulants; Factor Xa Inhibitors; Female; Hematoma, Epidural, Spinal; Humans; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Heparin; Humans; Models, Economic; Morpholines; Rivaroxaban; Sweden; Thiophenes; Venous Thromboembolism | 2011 |
Dose of enoxaparin in review of rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Enoxaparin; Health Services; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enoxaparin; Humans; Middle Aged; Models, Economic; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?
Topics: Anticoagulants; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Humans; Morpholines; Ontario; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Prevention of venous thromboembolism in total knee and hip replacement.
Topics: Aged; Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Female; Hip Prosthesis; Humans; Morpholines; Obesity; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Premedication; Prosthesis Failure; Recurrence; Reoperation; Risk; Risk Factors; Rivaroxaban; Stockings, Compression; Thiophenes; Venous Thromboembolism | 2012 |
Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.
Topics: Acute Disease; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism | 2012 |
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Topics: Anticoagulants; Hemorrhage; Hip Joint; Humans; Knee Joint; Morpholines; Orthopedic Procedures; Registries; Research Design; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Enoxaparin; Germany; Humans; Morpholines; Multicenter Studies as Topic; National Health Programs; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Drug Administration Schedule; Female; Fondaparinux; Germany; Humans; Kaplan-Meier Estimate; Logistic Models; Longevity; Male; Middle Aged; Morpholines; Orthopedic Procedures; Polysaccharides; Postoperative Hemorrhage; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Enoxaparin; Hemarthrosis; Hemorrhage; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
Topics: Age Factors; Anticoagulants; Drug Interactions; Factor Xa; France; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamins | 2012 |
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Topics: Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Thiophenes; Venous Thromboembolism | 2012 |
New oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Simplifying venous thromboembolism management: a new and safer era.
Topics: Anticoagulants; Clinical Trials as Topic; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; South Africa; Thiophenes; Thrombectomy; Venous Thromboembolism | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Primary Prevention; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |